Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation
- Resource Type
- Authors
- Anna Maria Geretti; Andrew Ustianowski; David Dunn; Clifford Leen; Brendan Payne; Simon Collins; Oliver Stirrup; Valerie Delpech; Christophe Fraser; Caroline Sabin; Adam Lewszuk
- Source
- HIV Medicine
- Subject
- Adult
Male
0301 basic medicine
Oncology
medicine.medical_specialty
Anti-HIV Agents
HIV Infections
Subgroup analysis
Drug resistance
medicine.disease_cause
Rate ratio
Emtricitabine
03 medical and health sciences
0302 clinical medicine
Internal medicine
Virology
Drug Resistance, Viral
medicine
Humans
Pharmacology (medical)
Treatment Failure
030212 general & internal medicine
Tenofovir
UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort
Original Research
emtricitabine
Mutation
M184I
business.industry
Health Policy
Hazard ratio
Lamivudine
HIV
1103 Clinical Sciences
Resistance mutation
030112 virology
United Kingdom
M184V
Infectious Diseases
HIV-1
Drug Therapy, Combination
Female
lamivudine
business
medicine.drug
- Language
- English
OBJECTIVES: The aim of the study was to investigate whether lamivudine (3TC) or emtricitabine (FTC) use following detection of M184V/I is associated with better virological outcomes. METHODS: We identified people with viruses harbouring the M184V/I mutation in UK multicentre data sets who had treatment change/initiation within 1 year. We analysed outcomes of viral suppression (